Heart failure drug trial ends early – only 4 patients enrolled

NCT ID NCT06581159

Terminated Disease control Sponsor: 35Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This was a very early (Phase 1) study testing a drug called HS135 in obese patients who have both pulmonary hypertension and a type of heart failure called HFpEF. The trial was terminated after enrolling only 4 people, so we have no useful information on whether HS135 is safe or effective. The main goal was to check for side effects and measure how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS135
What this could lead to: If it had worked, HS135 might have pointed toward a new treatment for obese patients with pulmonary hypertension and heart failure.
What could go wrong: This trial was terminated early with only 4 participants, so no conclusions can be drawn. It was a very early Phase 1 safety study, and the drug may not have been effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION PULMONARY HYPERTENSION

Contacts and locations

Locations

Site-104

Phoenix, Arizona, 85016, United States
Site-105

Kansas City, Missouri, 64111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.